Cargando…
Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib
Cervical cancer is caused by high-risk human papillomavirus (HPV) types and treated with conventional chemotherapy with surgery and/or radiation. HPV E6 and E7 proteins increase phosphorylation of retinoblastoma (Rb) by cyclin D1/cyclin dependent kinase (CDK)4/6 complexes. We hypothesized that cycli...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281234/ https://www.ncbi.nlm.nih.gov/pubmed/32429557 http://dx.doi.org/10.3390/cancers12051269 |
_version_ | 1783543875395125248 |
---|---|
author | Kennedy, Amy L. Rai, Rajani Isingizwe, Zitha Redempta Zhao, Yan Daniel Lightfoot, Stanley A. Benbrook, Doris M. |
author_facet | Kennedy, Amy L. Rai, Rajani Isingizwe, Zitha Redempta Zhao, Yan Daniel Lightfoot, Stanley A. Benbrook, Doris M. |
author_sort | Kennedy, Amy L. |
collection | PubMed |
description | Cervical cancer is caused by high-risk human papillomavirus (HPV) types and treated with conventional chemotherapy with surgery and/or radiation. HPV E6 and E7 proteins increase phosphorylation of retinoblastoma (Rb) by cyclin D1/cyclin dependent kinase (CDK)4/6 complexes. We hypothesized that cyclin D1 degradation by the SHetA2 drug in combination with palbociclib inhibition of CDK4/6 activity synergistically reduces phosphorylated Rb (phospho-Rb) and inhibits cervical cancer growth. The effects of these drugs, alone, and in combination, were evaluated in SiHa and CaSki HPV-positive and C33A HPV-negative cervical cancer cell lines using cell culture, western blots and ELISA, and in a SiHa xenograft model. Endpoints were compared by isobolograms, ANOVA, and Chi-Square. In all cell lines, combination indexes documented synergistic interaction of SHetA2 and palbociclib in association SHetA2 reduction of cyclin D1 and phospho-Rb, palbociclib reduction of phospho-Rb, and enhanced phospho-Rb reduction upon drug combination. Both drugs significantly reduced phospho-Rb and growth of SiHa xenograft tumors as single agents and acted additively when combined, with no evidence of toxicity. Dilated CD31-negative blood vessels adjacent to, or within, areas of necrosis and apoptosis were observed in all drug-treated tumors. These results justify development of the SHetA2 and palbociclib combination for targeting phospho-Rb in cervical cancer treatment. |
format | Online Article Text |
id | pubmed-7281234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72812342020-06-15 Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib Kennedy, Amy L. Rai, Rajani Isingizwe, Zitha Redempta Zhao, Yan Daniel Lightfoot, Stanley A. Benbrook, Doris M. Cancers (Basel) Article Cervical cancer is caused by high-risk human papillomavirus (HPV) types and treated with conventional chemotherapy with surgery and/or radiation. HPV E6 and E7 proteins increase phosphorylation of retinoblastoma (Rb) by cyclin D1/cyclin dependent kinase (CDK)4/6 complexes. We hypothesized that cyclin D1 degradation by the SHetA2 drug in combination with palbociclib inhibition of CDK4/6 activity synergistically reduces phosphorylated Rb (phospho-Rb) and inhibits cervical cancer growth. The effects of these drugs, alone, and in combination, were evaluated in SiHa and CaSki HPV-positive and C33A HPV-negative cervical cancer cell lines using cell culture, western blots and ELISA, and in a SiHa xenograft model. Endpoints were compared by isobolograms, ANOVA, and Chi-Square. In all cell lines, combination indexes documented synergistic interaction of SHetA2 and palbociclib in association SHetA2 reduction of cyclin D1 and phospho-Rb, palbociclib reduction of phospho-Rb, and enhanced phospho-Rb reduction upon drug combination. Both drugs significantly reduced phospho-Rb and growth of SiHa xenograft tumors as single agents and acted additively when combined, with no evidence of toxicity. Dilated CD31-negative blood vessels adjacent to, or within, areas of necrosis and apoptosis were observed in all drug-treated tumors. These results justify development of the SHetA2 and palbociclib combination for targeting phospho-Rb in cervical cancer treatment. MDPI 2020-05-17 /pmc/articles/PMC7281234/ /pubmed/32429557 http://dx.doi.org/10.3390/cancers12051269 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kennedy, Amy L. Rai, Rajani Isingizwe, Zitha Redempta Zhao, Yan Daniel Lightfoot, Stanley A. Benbrook, Doris M. Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib |
title | Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib |
title_full | Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib |
title_fullStr | Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib |
title_full_unstemmed | Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib |
title_short | Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib |
title_sort | complementary targeting of rb phosphorylation and growth in cervical cancer cell cultures and a xenograft mouse model by sheta2 and palbociclib |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281234/ https://www.ncbi.nlm.nih.gov/pubmed/32429557 http://dx.doi.org/10.3390/cancers12051269 |
work_keys_str_mv | AT kennedyamyl complementarytargetingofrbphosphorylationandgrowthincervicalcancercellculturesandaxenograftmousemodelbysheta2andpalbociclib AT rairajani complementarytargetingofrbphosphorylationandgrowthincervicalcancercellculturesandaxenograftmousemodelbysheta2andpalbociclib AT isingizwezitharedempta complementarytargetingofrbphosphorylationandgrowthincervicalcancercellculturesandaxenograftmousemodelbysheta2andpalbociclib AT zhaoyandaniel complementarytargetingofrbphosphorylationandgrowthincervicalcancercellculturesandaxenograftmousemodelbysheta2andpalbociclib AT lightfootstanleya complementarytargetingofrbphosphorylationandgrowthincervicalcancercellculturesandaxenograftmousemodelbysheta2andpalbociclib AT benbrookdorism complementarytargetingofrbphosphorylationandgrowthincervicalcancercellculturesandaxenograftmousemodelbysheta2andpalbociclib |